169 related articles for article (PubMed ID: 31782130)
21. [Parathyroid carcinoma].
Krysiak R; Okopień B
Pol Merkur Lekarski; 2007 Aug; 23(134):145-50. PubMed ID: 18044348
[TBL] [Abstract][Full Text] [Related]
22. Human parathyroid hormone. Immunological characterization of antibodies against a glandular extract and the synthetic amino-terminal fragments 1-12 and 1-34 and their use in the determination of immunoreactive hormone in human sera.
Fischer JA; Binswanger U; Dietrich FM
J Clin Invest; 1974 Dec; 54(6):1382-94. PubMed ID: 4474187
[TBL] [Abstract][Full Text] [Related]
23. Parathyroid carcinoma.
Kebebew E
Curr Treat Options Oncol; 2001 Aug; 2(4):347-54. PubMed ID: 12057115
[TBL] [Abstract][Full Text] [Related]
24. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma.
Betea D; Bradwell AR; Harvey TC; Mead GP; Schmidt-Gayk H; Ghaye B; Daly AF; Beckers A
J Clin Endocrinol Metab; 2004 Jul; 89(7):3413-20. PubMed ID: 15240624
[TBL] [Abstract][Full Text] [Related]
25. Parathyroid carcinoma: a 22-year experience.
Busaidy NL; Jimenez C; Habra MA; Schultz PN; El-Naggar AK; Clayman GL; Asper JA; Diaz EM; Evans DB; Gagel RF; Garden A; Hoff AO; Lee JE; Morrison WH; Rosenthal DI; Sherman SI; Sturgis EM; Waguespack SG; Weber RS; Wirfel K; Vassilopoulou-Sellin R
Head Neck; 2004 Aug; 26(8):716-26. PubMed ID: 15287039
[TBL] [Abstract][Full Text] [Related]
26. Parathyroid carcinoma: evaluation and interdisciplinary management.
Clayman GL; Gonzalez HE; El-Naggar A; Vassilopoulou-Sellin R
Cancer; 2004 Mar; 100(5):900-5. PubMed ID: 14983483
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and management of thyroid and parathyroid hyperplasia and neoplasia.
Sloan DA; Schwartz RW; McGrath PC; Kenady DE
Curr Opin Oncol; 1995 Jan; 7(1):47-55. PubMed ID: 7696363
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue.
Corbetta S; Vaira V; Guarnieri V; Scillitani A; Eller-Vainicher C; Ferrero S; Vicentini L; Chiodini I; Bisceglia M; Beck-Peccoz P; Bosari S; Spada A
Endocr Relat Cancer; 2010 Mar; 17(1):135-46. PubMed ID: 19926710
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid Cancer in the Pediatric Patient.
Davidson JT; Lam CG; McGee RB; Bahrami A; Diaz-Thomas A
J Pediatr Hematol Oncol; 2016 Jan; 38(1):32-7. PubMed ID: 26650250
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell immunotherapy induces antitumour response in parathyroid carcinoma and neuroendocrine pancreas carcinoma.
Schott M; Seissler J; Feldkamp J; von Schilling C; Scherbaum WA
Horm Metab Res; 1999 Dec; 31(12):662-4. PubMed ID: 10668919
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital.
Erovic BM; Goldstein DP; Kim D; Mete O; Brierley J; Tsang R; Freeman JL; Asa SL; Rotstein L; Irish JC
Head Neck; 2013 Jan; 35(1):35-9. PubMed ID: 22290780
[TBL] [Abstract][Full Text] [Related]
32. Parathyroid carcinoma: challenges in diagnosis and treatment.
Mohebati A; Shaha A; Shah J
Hematol Oncol Clin North Am; 2012 Dec; 26(6):1221-38. PubMed ID: 23116578
[TBL] [Abstract][Full Text] [Related]
33. Carboxyl-terminal fragments of human parathyroid hormone in parathyroid tumors: unique new source of immunogens for the production of antisera potentially useful in the radioimmunoassay of parathyroid hormone in human serum.
Di Bella FP; Gilkinson JB; Flueck J; Arnaud CD
J Clin Endocrinol Metab; 1978 Apr; 46(4):604-12. PubMed ID: 755044
[TBL] [Abstract][Full Text] [Related]
34. Primary and metastatic parathyroid malignancies: a rare or underdiagnosed condition?
Shifrin A; LiVolsi V; Shifrin-Douglas S; Zheng M; Erler B; Matulewicz T; Davis J
J Clin Endocrinol Metab; 2015 Mar; 100(3):E478-81. PubMed ID: 25490272
[TBL] [Abstract][Full Text] [Related]
35. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma.
Horie I; Ando T; Inokuchi N; Mihara Y; Miura S; Imaizumi M; Usa T; Kinoshita N; Sekine I; Kamihara S; Eguchi K
Endocr J; 2010; 57(4):287-92. PubMed ID: 20051648
[TBL] [Abstract][Full Text] [Related]
36. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid carcinoma: 50-year experience at The Cleveland Clinic Foundation.
Hakaim AG; Esselstyn CB
Cleve Clin J Med; 1993; 60(4):331-5. PubMed ID: 8339458
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study.
Villar-del-Moral J; Jiménez-García A; Salvador-Egea P; Martos-Martínez JM; Nuño-Vázquez-Garza JM; Serradilla-Martín M; Gómez-Palacios A; Moreno-Llorente P; Ortega-Serrano J; de la Quintana-Basarrate A
Surgery; 2014 Nov; 156(5):1132-44. PubMed ID: 25444314
[TBL] [Abstract][Full Text] [Related]
39. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
40. Intracranial metastatic parathyroid carcinoma: case report.
Tyler D; Mandybur G; Dhillon G; Fratkin J
Neurosurgery; 2001 Apr; 48(4):937-9; discussion 939-40. PubMed ID: 11322456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
